|Bid||6.93 x 800|
|Ask||6.94 x 900|
|Day's Range||6.87 - 7.28|
|52 Week Range||6.26 - 22.00|
|Beta (3Y Monthly)||1.76|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||26.33|
Abeona Therapeutics Inc. (ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced that it has appointed Christine Silverstein to the position of Chief Financial Officer and named Edward Carr as Chief Accounting Officer.
Tim Miller has been the CEO of Abeona Therapeutics Inc. (NASDAQ:ABEO) since 2015. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of Read More...
“Market conditions are changing. The continued rise in interest rates suggests we are in the early stages of a bond bear market, which could intensify as central banks withdraw liquidity. The receding tide of liquidity will start to reveal more rocks beyond what has been exposed in emerging markets so far, and the value of […]
Abeona Therapeutics (ABEO) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
EB-101 pivotal trial for Recessive Dystrophic Epidermolysis Bullosa planned for mid-2019 enrollment Expanding Phase I/II study of ABO-102 for Sanfilippo syndrome type A (MPS.
Abeona Therapeutics Inc. (ABEO) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Abeona Therapeutics Inc. (ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced the immediate termination of its Chief Executive Officer, Dr. Carsten Thiel due to personal misconduct that violated the Company’s Code of Business Conduct and Ethics.
NEW YORK and CLEVELAND, Nov. 13, 2018 -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene.
Abeona Therapeutics (ABEO) delivered earnings and revenue surprises of -47.83% and 68.04%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Dallas-based company said it had a loss of 34 cents. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was ...
Investor Conference Call on Monday, November 12th at 10:00 a.m. ET NEW YORK and CLEVELAND, Nov. 09, 2018 -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage.
If you own shares in Abeona Therapeutics Inc (NASDAQ:ABEO) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure Read More...
Abeona granted new licenses to NAV AAV9 for the development and commercialization of treatments for MPS IIIA, MPS IIIB, CLN1 and CLN3 Batten Disease Abeona to pay REGENXBIO $20.
ROCKVILLE, Md., Nov. 5, 2018 /PRNewswire/ -- REGENXBIO Inc. (RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, and Abeona Therapeutics Inc. (ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced a license agreement to REGENXBIO's NAV AAV9 vector for the treatment of four diseases: Sanfilippo syndrome type A (MPS IIIA), Sanfilippo syndrome type B (MPS IIIB), Infantile Batten Disease, also known as neuronal ceroid lipofuscinosis type 1 (CLN1 Disease), and Juvenile Batten Disease, also known as neuronal ceroid lipofuscinosis type 3 (CLN3 Disease).
Yesterday, Abeona Therapeutics (ABEO) stock closed at $13, ~75% below its 52-week high of $22.75 on October 11, 2017. This month, Abeona stock has fallen 15% from $15.40 on August 31. Abeona’s 52-week low is $10.50, which it reached on February 15.
Abeona Therapeutics Inc’s (NASDAQ:ABEO): Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. With the latest financial yearRead More...
BioLife Solutions (BLFS) generated a net income of $1.05 million in the second quarter compared to a net loss of $768,212 in the second quarter of 2017. That translates to net income per share of $0.05 in the second quarter. Its net loss per share was $0.06 in the second quarter of 2017.